When the COVID-19 pandemic began its outbreak in 2020, the biopharmaceutical industry began its work on developing a vaccine. The vaccines by Moderna and Pfizer-BioNTech using messenger RNA, or mRNA, emerged.
Due to challenges with distribution specificity and stability within the body, until now, mRNA has had a slow uptake in the industry. Scientific advances and an increase in resources and focus dedicated to mRNA research and development during the COVID-19 response have demonstrated its potential as a disruptive technology for the future of medicine.
However, there are still hurdles when it comes to efficient and effective process development of mRNA vaccines and therapies. Key areas and strategies can help alleviate bottlenecks in the growing market segment for mRNA.